ArticleFrontiers in neurology
The systemic immune-inflammation index as a superior predictor of functional outcome following mechanical thrombectomy for acute ischemic stroke: a retrospective cohort study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systemic immune-inflammation index, stress hyperglycemia ratio and triglyceride-glucose index in acute ischemic stroke: an integrated inflammation-stress-metabolism perspective.Frontiers in neurology · 2026Review
- Associations of nine composite inflammatory indices with clinical outcomes after mechanical thrombectomy for acute ischemic stroke: a single-center retrospective study.Frontiers in neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Despite high recanalization rates with mechanical thrombectomy (MT) for acute ischemic stroke (AIS), functional outcomes remain variable. Systemic inflammation is a key driver of secondary brain injury post-reperfusion. The systemic immune-inflammation index (SII), calculated as (platelet count × neutrophil count)/lymphocyte count, integrates multiple inflammatory pathways and has shown prognostic value in cardiovascular diseases and stroke treated with intravenous thrombolysis. However, its role in predicting outcomes specifically for AIS patients undergoing MT remains underexplored. This study aimed to develop and validate an SII-based model for predicting 90-day functional outcomes after MT and to compare its performance with traditional inflammatory biomarkers, namely neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). Methods: We retrospectively analyzed data from 387 AIS patients treated with MT. The cohort had a median age of 68 years [interquartile range (IQR): 59-75], 67.2% were male, and the median time from stroke onset to thrombectomy was 340 min (IQR: 242.5-465.5). Inflammatory markers were measured at admission, such as SII, platelet lymphocyte ratio (PLR), neutrophil lymphocyte ratio (NLR) and 90-day modified Rankin Scale (mRS) scores. Patients were divided into good (90-day mRS ≤ 2; Results: SII alone showed higher predictive accuracy (AUC: 0.834) than PLR or NLR. The optimal model (baseline + SII) achieved an AUC of 0.863, significantly improving outcome prediction over the baseline model (AUC: 0.655). Shapley Additive exPlanations (SHAP) analysis confirmed SII as the most influential variable (74.2% contribution). The model demonstrated good calibration and clinical utility across a range of probability thresholds. Conclusion: A model incorporating the SII provides superior accuracy for predicting 90-day functional outcome after MT compared to models using NLR or PLR. As an easily obtainable composite biomarker, SII enhances risk stratification and could aid early clinical decision-making for AIS patients undergoing endovascular therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.